Solid Biosciences Inc.

Duchenne muscular dystrophy

Solid Biosciences Inc. focuses on neuromuscular disease research, with activity centered on Duchenne muscular dystrophy and the development of gene therapy approaches aimed at restoring microdystrophin expression in muscle tissue.

  • Muscle biopsy biomarker assessment
  • Microdystrophin expression
  • Intravenous gene delivery

The sponsor’s clinical research interest is concentrated on treatment strategies for the genetic basis of Duchenne muscular dystrophy, with emphasis on skeletal muscle function and disease-related protein restoration.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of SGT-003 Gene Therapy for Safety and Tolerability in Walking Males with Duchenne Muscular Dystrophy

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

    Not yet recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain